comprehens dmd platform led gene therapi despit high
expect dmd gene therapi program see room continu
share appreci program develop expect initi data
three clinic stage gene therapi program like demonstr
robust dystrophin express skelet muscl think srpt mover
advantag strong initi data set high bar strong competit
posit long-term point clinic differenti may emerg
exampl suggest construct may produc greater dystrophin
capsids/promot use could provid support hypothesi
think preclin evid
heart
substanti dmd may yield one gene therapi
blockbust model market share peak sale
approach annual recur revenu run-rat long-term
steadi newsflow pipelin anticip addit
dmd gene therapi data octob expect initi clinic
data srpt lgmd gene therapi program
annual revenu opportun deliv initi muscl biopsi data
earli also expect regulatori file srpt pmo address
exon skip complement srpt commerci exon
skip exondi franchis dmd come month
earli safety/dos escal srpt next-gen ppmo program dmd
earli successor srpt commerci pmo product exondi
togeth believ srpt pmo/ppmo offer support valuat
floor absenc gene therapi
initi outperform target price valuat base
sotp dcf dmd gene therapi key compon
risk includ clinic regulatori commerci headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
sarepta biotechnolog compani focus develop
gene therapi rna-target therapeut compani
primarili focus develop duchenn muscular dystrophi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario reflect probabl success
dmd gene therapi probabl success
lgmd gene therapi probabl success
casimersen golodirsen
grey sky scenario reflect valu dmd gene
therapi valu lgmd gene therapi premium
 close
initi coverag outperform rate target price
profound earli efficaci micro-dystrophin gene therapi program first mover
posit suggest well-posit becom standard care dmd addit
data readout commenc registr cohort on-going trial
keep srpt gene therapi program firmli investor radar meanwhil
pmo/ppmo exon skip platform includ market product exondi
multipl late-stag pmo clinic candid next-gener early-stag
candid set attract floor valuat stock absenc
potenti proof-of-concept result lead candid expect
collect srpt five lgmd gene therapi candid could contribut
recur annual revenu
micro-dystrophin gene therapi result first three patient indic potenti
meaning function benefit patient observ ascend stair reciproc
run program clinic hold current batch abnorm
comfort issu resolv dose addit patient
gate step regulatori file complet manufactur technolog transfer
expect end think biopsi crossov patient cohort
dose commerci materi could support nda file
acceler approv expect vast major dmd patient eventu
treat gene therapi believ market larg enough support multipl
player solid also program expect deliv encourag
initi dystrophin express biopsi data long-term clinic differenti tbd
think avail evid lend support srpt belief differenti
capsid promot may confer better cardiac transduct
compet approach assign dmd gene therapi market
recur revenu
credit suiss biotech short-term outlook expect investor focu
dmd micro-dystrophin data readout octob evid durabl
benefit srpt initi four dose patient watch investor
balanc competitor updat
credit suiss biotech long-term outlook expect investor focus
timelin technolog transfer commenc pivot studi well
micro-dystrophin gene therapi result also expect
heighten focu lgmd program poc result pmo/ppmo
platform two possibl approv next month
credit suiss biotech outlook believ leadership posit
major emerg therapeut indic dmd key first mover edg gene therapi
result compani attract candid see key element
derisk complet manufactur scale-up clarif regulatori timelin
definit competit posit
seen gene therapi trial evid
benefit hand patient significantli derisk
program futur data updat patient longer durat
posit earli data set high bar competitor dmd
gene therapi becom standard care captur
major market
earli efficaci promis signific unknown remain
efficaci may wane follow longer durat treatment
unclear gene therapi effect older patient
long-term safeti micro-dystrophin gene therapi
determin lastli competit threat limit upsid opportun
srpt product differenti unclear
believ srpt earli micro-dystrophin gene therapi data highli compel set high bar competitor
acknowledg long-term safeti durabl unknown preclin model suggest multi-year efficaci safeti
expect recept regulatori environ dmd given sever diseas lack treatment option model
market share translat annual recur revenu
clinic hold relat out-of-specif manufactur
batch rel minor quickli address
technolog transfer complet pave way
acceler regulatori file
manufactur underappreci risk clinic hold
could sign thing come may take signific time
clear delay technolog transfer push timelin
commenc pivot trial enabl competitor
catch
believ clinic hold effici remov larger hurdl opinion technolog transfer expect
process complet howev believ timelin could risk ultim expect fda want see
patient dose commerci materi prior approv addit may requir significantli commerci product
avx sinc averag treat dmd patient heavier compani use similar manufactur approach avx
build second facil meet commerci demand
exondi still earli commerci launch achiev
annual sale long term golodirsen like
approv base increas dystrophin given
exondi preced casimersen approv
provid yet anoth approv pmo ppmo
program establish competit advantag even
face competit srpt lgmd gene therapi program
meanwhil could ultim address market one-third
size dmd without competit
exondi shown function benefit found
increas dystrophin level meanwhil casimersen
golodirsen dont appear much better term dystrophin
express level rais risk approv open
opportun competitor demonstr superior clinic
profil product rare use gene therapi
come market natur histori lgmd poorli character
make market opportun clinic develop path
discuss expert suggest benefit exondi like golodirsen casimersen modest howev
product use given lack treatment option think srpt uniqu posit dmd gene therapi dmd
pmo/ppmo enabl effect combat competit threat see limit continu role exon-skip therapi
gene therapi introduct lgmd gene therapi develop larg unoppos competit compani commit beyond
dmd strengthen srpt commerci effort see peak valu potenti lgmd valu total dmd gene
updat result studi clariti file
file ind
nda submiss base dystrophin improv
essenc wk biopsi support possibl
possibl nda submiss base dystrophin
ind submiss sever ppmo
casimersen
dose patient sinc remov clinic hold
data updat like initi patient
fall possibl
price gene therapi treatment
sma implic dmd gene therapi price
let hear boy dmd gene therapi
srpt micro-dystrophin program demonstr compel efficaci first
three patient dose addit data first four patient dose expect
clinic differenti vs solid approach may appar
lt data accru sarepta believ micro-dystrophin construct
choic capsid may result favor cardiac dystrophin express
think could bear evid support improv cardiac transduct use
similar sarepta capsid vs solid/pf
sarepta narrow first-mov advantag gene therapi space provid
anoth potenti competit benefit believ sarepta could enter market
follow acceler approv path compani narrow
first-mov advantag give edg address preval dmd
long-term model sarepta gene therapi captur recur
annual opportun note differenti capsid major posit
sarepta could captur nearli redos opportun initi
treat capsid therapi
duchenn muscular dystrophi dmd progress muscl wast diseas afflict
patient unit state us annual incid
patient diseas character loss ambul second decad
life inabl perform everyday activ biolog diseas well
character diseas result loss function mutat dystrophin
gene lead insuffici dystrophin product
onset
us eu
gener yr age
dystrophin full gene larg fit aav capsid
patient dmd neglig product protein dystrophin critic
muscl fiber strength/stabl
exon popul
exon popul
exon popul
nonsens mutat popul
cardiomyopathi respiratori insuffici profound muscl wast
loss ambul gener age
death commonli late teen even treatment
prednison emflaza
translarna approv exu patient nonsens mutat
exondi approv us patient amen exon skip
dmd treatment current gener consist steroid shown delay
loss ambul support care addit srpt exondi approv
us ptc translarna approv europ nich segment popul
none exist therapi convey signific benefit long-term prognosi poor
even current standard care life expect year age death
often result cardiac respiratori failur
sarepta develop micro-dystrophin gene therapi treatment dmd
therapi util capsid promot deliv truncat version
human dystrophin gene heart skelet muscl therebi prompt micro-
dystrophin protein product gene therapi approach theoret address
entir dmd popul see figur compar current approach avail
patient segment specif mutat
figur percentag dmd popul potenti amen exon skip
potenti
address
believ compel proof-of-concept result report first three patient
dose vg/kg on-going clinic trial substanti derisk program
day follow treatment muscl fiber dystrophin posit addit
treatment result mean micro-dystrophin express compar normal
muscl tissu unadjust presenc fat fibrot tissu result
applaud present sarepta june day repres possibl
breakthrough dmd treatment see figur context sarepta exondi
approv base achiev dystrophin express expert believ
dystrophin express significantli improv diseas phenotyp close
patient becker muscl dystrophi relat less sever condit ambul
sustain later life life expect
therapi also result dramat reduct creatin kinas biomark
suggest micro-dystrophin express may lead restor
dystrophin associ protein complex allow reduc muscl inflamm
improv stabil repair mechan figur
number patient
month yr
mutat exon
averag bayley-iii
motor assess gross motor
defin scale score
previou treatment
mutat exon
averag meter
time test defin
stabl steroid least wk
sign cardiomyopathi includ
echocardiogram eject fraction
subject
sign cardiomyopathi includ
echocardiogram eject fraction
subject
random crossov yr
chang micro-dystrophin
decreas ck
chang micro-dystrophin
decreas ck
time go
ascend descend step
chang micro-dystrophin
decreas ck
time go
ascend descend step
ck level baselin
express compar
vector copi per nuclei translat micro-dystrophin posit fiber
adjust fat/fibrot tissu
adjust fat fibrot tissu
importantli micro-dystrophin appear convey function benefit patient
abl ascend stair reciproc day treatment someth unabl
two day gene therapi addit video evidenc patient ascend stair
reciproc patient abl run day gene therapi treatment
major said gene therapi trial evid potenti
immunogenic-driven attribut high vector dose may necessit complex
believ unlik result due chang steroid regimen
patient stabl steroid come trial patient receiv one high
dose steroid prior gene transfer patient receiv second high dose
steroid gene transfer expert mention steroid make patient stronger
short term lower ck level benefit usual short-
live expert opinion steroid could driver profound benefit
observ clinic biomark
statu clinic trial
expect heavi newsflow program next month updat
result first four patient dose expect addit clinic updat throughout
posit result continu derisk program current appli
probabl success
dose new patient hold sinc juli hold result
trace level dna fragment research-grad raw materi found plasmid
sourc third-parti manufactur even though batch found dna
fragment administ patient prior lot use third-
parti plasmid use dose four patient biopsi patient find
dna fragment foreign protein safeti issu emerg expect
compani decis use gmp sourc plasmid move forward fulli resolv
issu anticip lift clinic hold upon lift hold
expect sarepta resum dose new cohort includ commenc
registr path cohort crossov studi
dmd gene therapi durabl respons tbd reason optim exist
date durabl express micro-dystrophin seen two year dog
model le guiner et al srpt construct raav promot
addit muscle-target gene therapi shown durabl
long-term durabl micro-dystrophin express human unknown see
reason expect multi-year benefit key determin long-term gene express
turnov rate underli tissu target therapi rel liver-target
gene therapi hemophilia must contend uncertainti around durabl
limit hepatocyt turnov dmd gene therapi target heart skelet muscl
cell cell turnov rel substanti reduc number cardiomyocyt
remain constant human lifespan limit turnov cell
see figur birth rate year old birth rate adult bergmann
averag lifespan skelet muscl year healthi patient much
shorter patient dmd howev unlik heart skelet muscl mass increas
throughout childhood figur given nonintegr natur aav gene therapi
possibl new muscl mass establish gene therapi administr may
experi dilut effect function micro-dystrophin final import note
matur dmd patient experienc degre fat fibrot deposit
muscl result repeat damage/repair cycl owe underli diseas
could impact benefit micro-dystrophin and/or therapeut durabl
sarepta differenti capsid vs pfizer/solid may posit
redos gene therapi choic patient initi receiv either compet gene
therapi sinc capsid immunogen thought key factor limit redos
higher cell turnov younger patient
figur amount skelet muscl
significantli increas first year life
acceler approv path probabl manufactur could gate step
think acceler approv sarepta gene therapi possibl base upon cohort
 result on-going studi exact design yet confirm
pend discuss fda later year earli indic cohort
placebo-control trial patient random crossov one year
cohort initi dose patient clinic trial materi aim treat
crossov patient one year commercial-scal gene therapi product believ
path file approv could conting success confirm
commercial-scal product produc compar dystrophin express level
biopsi exampl clinic benefit observ increas
dystrophin express either via function sign and/or biomark ck
decreas trial support file expect fda requir
cohort patient treat commerci product initi
biopsi data meanwhil sarepta like want confid scale-up process
place ensur ampl drug suppli product launch ahead file sinc demand
launch product like signific
compani develop hybrid gene therapi manufactur approach sarepta
develop intern expertis aav manufactur brammer provid
scalabl manufactur capabl agreement brammer establish
june sarepta expect complet technolog transfer nch
complet
avexiss experi sma offer reason compar situat util
adherent-cel system construct initi develop nch
demonstr profound benefit sma gene therapi studi
fda request commenc registr studi demonstr activ
commercial-scal product follow technolog transfer nationwid children
hospit prior subsequ file approv sma expect
base preced confid sarepta abil transfer gene therapi
process success move commerci product within month coupl
note investor may want consid avexiss experi
scale-up avx took littl year novarti
announc anoth facil construct north carolina
suppli type sma opportun avx first mention
nch technolog transfer issu march
pivot type studi commend septemb
addit novarti expect new facil take two year
complet indic sarepta manufactur process
similar avxss approach adherent-cel system
initi process also origin nch learn avexiss
regulatori experi coupl brammer capac suggest
sarepta improv upon avexiss timelin anticip
compani could commerci product readi clinic studi within
month ye
need produc drug avx expect
patient dose micro-dystrophin averag heavier
patient dose therapi dose vg/kg
sarepta comment collabor brammer expect
yield greatest gene therapi product capac exist
base scenario assum patient enrol double-blind portion pivot trial
dose clinic suppli patient crossov round dose
commerci suppli allow rapid approv path double-blind phase studi
expect start later year earli next year given high unmet need trial
enrol rapidli patient crossov arm like dose earli
expect may abl file approv soon biopsi
data avail patient crossov arm assumpt acceler
approv path end base fda guidanc gene therapi develop
real-world regulatori experi develop
addit cohort support approv believ label expans beyond
inclus popul plan cohort could support companion studi
contempl could includ treat older and/or younger patient
includ nonambulatori patient dmd patient broader rang mutat
expect support cohort may also commenc enrol ye pend
drug suppli lift clinic hold
solid also current develop clinical-stag dmd gene therapi
compani expect initi result within next month base
preclin result expect compet product like offer substanti
increas biopsy-measur dystrophin express potenti earli efficaci sign
demonstr sarepta long-term data like need
fulli compar product base model assum three product initi profil
rel similar
like provid data patient across two dose cohort one-year
dose mark think would like fall interim biopsi data
could avail even ye initi low-dos cohort solid
state data updat expect anticip may
possibl timelin interim biopsi result depend rapidli compani
abl dose escal phase trial resum expect
charl martineau pm univers toronto new therapi high unmet need consider pent-up
demand first-mov advantag signific ultim expect first-mov
one major factor determin market share product profil develop
figur comparison clinic program
open-label cohort dose cohort
patient total ambulatori non-ambulatori
patient total ambulatori
number patient
cohort ambulatori
cohort
 us
month yr
mutat exon
averag bayley-iii motor assess
gross motor defin scale score
previou treatment steroid month
stabl steroid least wk yr old
vg/kg disclos think higher
dose need could vg/kg
 univ florida
establish clinic diagnosi dmd
document dystrophin gene mutat predict
confirm absenc dystrophin determin
antibodi protocol-specifi
adolesc non-ambulatori protocol-specifi
children ambulatori protocol-specifi criteria
stabl daili dose oral corticosteroid wk
sign cardiomyopathi includ echocardiogram
eject fraction
subject antibodi titer
exposur drug affect dystrophin utrophin
express within month prior screen
compani disclos dose compar
preclin studi think scale
vg/kg vg/kg
 us duke ucla univ utah
diagnosi duchenn muscular dystrophi
confirm medic histori genet test
bodi weight kg
receipt glucocorticoid month stabl
daili dose least month prior studi entri
neutral antibodi nab adeno-
associ viru serotyp pre-exist anti-
compromis cardiac function indic left
ventricular eject fraction less
prior exposur gene therapi agent includ
exon-skip missens agent
chang micro-dystrophin express pre vs post
decreas ck
time go
ascend descend step
cardiac mri
chang baselin microdystrophin express
muscl biopsi activ treatment group
evid mini-dystrophin express
distribut assess immunohistochemistri western
time frame baselin month year post-
therapi produc promis preclin efficaci profil although
micro-dystrophin gene dmd gene largest gene human bodi
compris exon result size constraint aav
vector packag capac aav gene therapi provid
full dystrophin gene differ gene therapi develop elect
include/exclud certain domain base interpret featur
may ultim produc optim clinic respons
concept micro-dystrophin aros discoveri larg delet
within dystrophin gene associ extrem mild case bmd
england et al construct slight variat
includ actin bind domain hing cysteine-rich domain preclin
data publish present three clinical-stag program support
expect robust dystrophin express earli clinic test
charl martineau pm univers toronto figur compani therapi construct slightli differ
promot promot control express therapeut gene often
tissu specif activ certain cell type dmd gene therapi
target skelet heart muscl effect sarepta program
util promot solid construct util promot
public formerli product refer use
promot differ awar two
promot includ cardiac-specif enhanc
promot hand approxim smaller
goncalv et al possibl make attract solid
may save space allow inclus fifth spectrin-lik repeat region
capsid sarepta gene therapi util capsid similar
solid use capsid numer publish
mous studi suggest capsid effect transduc skelet
cardiac muscl tissu publish preclin evid univers
missouri lab dr duan lead scientif advisor solidwhich use
pioneer solid gene therapi program support
effici cardiac gene transduct neonat dog pan
duan et al human gene ther method public lab
suggest cardiac transduct young adult dystroph dog may limit
yue duan et al mol ther base public grant
report updat duan et al appear univers missouri lab
current evalu novel capsid solid micro-
dystrophin gene construct promot next gener gene therapi
unclear signific differ literatur support
approach instanc paper js chamberlain et al found
promot effect promot studi author time support
sarepta decis use promot cassett howev author
subsequ author solid preclin studi use newer promot
sarepta design built optim effort made mendel construct
origin lab nch sarepta indic preclin work
includ evalu larg number possibl combin manag feel
attract efficaci trade-off come inclus believ
support forc gener protect muscl damag
micro-dystrophin includ nno preclin model found nnos-restor
micro-dystrophin contain within spectrin-lik repeat may
effect improv muscl function stabil lai et al
pfizer construct larg similar mendel construct key differ
choic vector vs promot human muscl specif
promot vs cmv patient mendel studi dose either vg/kg
vg/kg local inject bicep treatment fail establish
long-term transgen express like result immun respons four six
patient dose t-cell respons micro-dystrophin
figur preclin data three clinical-stag gene therapi program
vg/kg vg/kg
skelet muscl express
heart express
month follow-up
higher two dose dystrophin express heart
skelet muscl
evid anti-dystrophin t-cell
biopsi month
minim effect dose found vg/kg
dystrophin posit fiber month month bicep
dystrophin posit fiber month month diaphragm
dystrophin posit fiber month month cardiac muscl
dystrophin posit fiber month month bicep
dystrophin posit fiber month month diaphragm
dystrophin posit fiber month month cardiac muscl
drop ck level
protein seen host
immun system yet humor
respons detect
transgen product capsid
impact therapeut
efficaci test item
follow-up
vg correspond vg/kg
vg correspond vg/kg
vg correspond vg/kg
week note mdx
mous model mild
dystrophin posit fiber greater posit muscl fiber strong heart
express diaphragm dystrophin posit fiber vg/kg equival dose
dystrophin express heart rel skelet muscl
improv ck
vg dose data
provid dose
induc anatom lesion
muscl administr
observ deliveri micro-
dystrophin nhp
separ nhp
dose
clinician perspect ideal product profil
spoke multipl dmd expert determin ideal product profil dmd gene
minimum gene therapi delay loss ambul three
year ambul patient ideal clinician believ therapi could
move patient milder bmd-like phenotyp said given lack
treatment option delay loss ambul three five year suffici
compel use although suspect price power could limit without
profound clinic benefit
preserv respiratory/cardiac function compel use
nonambulatori patient expert believ gene therapi could strong
appeal patient nonambul believ gene therapi could
preserv
function may abl
consist respons patient expert would like see consist
predict respons therapi
closer normal micro-dystrophin express level better
dystrophin express therefor function benefit like declin
normal
micro-dystrophin express possibl
convey close
therapi aim
respiratory/cardiac improv could differenti cardiac
respiratori failur lead caus death dmd patient
expect gene therapi broadli rapidli adopt given high unmet need
howev addit data may need gener gain full penetr
dmd patient seven sarepta current studi protocol
investig dose patient three month seven year age
expect micro-dystrophin could effect older patient even lost
ambul expect gene therapi may reduc cardiomyopathi preserv
respiratori function even older patient ambul may partial
recover older patient could still benefit long term potenti
increas surviv cardiac respiratori issu lead caus
death dmd safeti older patient key gate step older patient
receiv total viral dose scale upper rang human exposur
patient non-exon mutat expert expect
micro-dystrophin prove function replac like effect
across dmd patient regardless mutat beyond scope sarepta
phase trial evalu individu exon mutat expect
clinic data gener time support gene therapi util
set support broader label reimburs
redosing/pati high antibodi current trial exclud
treat patient high antibodi estim
patient fall categori unrel work hemophilia current on-going
evalu dose patient high antibodi titer success
set could posit
srpt micro-dystrophin
encourag loosen inclus criteria futur studi
retreat differ dmd gene therapi dont current
model long term think patient may requir redos believ
well posit capit opportun sinc pfizer/solid
sarepta util differenti capsid opportun redos anoth
construct may possibl patient requir addit support later life
model attribut micro-dystrophin program base follow
probabl success /- chang raises/low npv
us price million gross net see launch price
sma meaning comp investor watch
gene therapi us market penetr account
redos gene therapi model could creat substanti upsid
sarepta market share base assumpt driven sarepta
lt potenti clinic differenti base cardiac express
expect adjust share assumpt up/down competit profil develop /-
chang market share lead raising/low npv
figur sensit analysi valu dmd gene therapi program
preval dmd
treat patient gene therapi year
year ent share yr peak
patient sarepta gene therapi
preval dmd
treat patient gene therapi year
patient sarepta gene therapi
pay perform net cost
preval dmd
treat patient gene therapi year
patient sarepta gene therapi
pay perform net cost
year ent share yr peak
year ent share yr peak
pmo platform provid commerci presenc
busi futur
model near-term growth srpt exon skip franchis buoy
continu uptak exondi us potenti approv casimersen
golodirsen
initi result next month srpt next-gener exon skip
asset along data competitor clarifi srpt posit
expect gene therapi becom foundat therapi choic
dmd boy pmo/ppmo may play smaller still signific part
environ pretreat efficaci add-on exact role tbd
srpt exon skip therapi provid downsid protect model
valuat rang long-term gene therapi environ
gene therapi come market
compar gene therapi aim provid function micro-dystrophin
exon-skip therapi repair dystrophin express specif mutat set
individu product address dmd popul exondi approv
treatment dmd patient amen exon skip two
addit asset golodirsen exon casimersen exon develop
potenti approv respect
figur percentag dmd popul potenti amen exon
potenti
address
pmo phosphorodiamid morpholino oligom monopoli posit
next-gener ppmo need sarepta sustain lt busi
competitor therapi activ develop compet exon skip
even gene therapi come market expect portion patient requir
addit dystrophin produc therapi suspect srpt entrench
commerci posit potenti abil offer competit price patient use
gene therapi exon skip product efficaci next-
gener ppmo compar first-gen pmo may insul franchis
potent exon skip threat develop wave nippon shinyaku daiichi
type therapi
receiv acceler approv
trial initi novemb safeti data
trial enrol patient singl ascend iv dose
plan efficaci studi could result
trial initi decemb data possibl later year
trial enrol patient ascend dose cohort
essenc trial confirmatori trial compani
track submit roll nda submiss base dystrophin
increas year-end allow target approv mid-
iv weekli us studi patient found dystrophin
product normal addit analysi expect fall
expect enter clinic
ppmo platform plan file ind
sarepta also ppmo preclin candid target exon
essenc trial patient enrol
compani hope wk biopsi data
support acceler approv talk fda trial wk
assess function endpoint
subcutan weekli per april top-line
express dystrophin partial identifi
clearli detect whole
ppmo platform possibl ind
dystrophin trial expect commenc support
clariti long-term competit pictur current lack emerg
come month plan present safeti data earli exon
ppmo initi dystrophin express data earli initi safeti
data next year abil dose escal could meaning derisk program ahead
dystrophin data would establish compani safe achiev dose
level confer efficaci compar pmo preclin model also
five ppmo asset current ind enabl toxicolog studi
could initi safeti data initi efficaci incl dystrophin express data
preclin model therapi demonstr dystrophin restor
compar first-gen eteplirsen analog achiev
updat result studi clariti file
file ind
nda submiss base dystrophin improv
essenc wk biopsi support possibl
possibl nda submiss base dystrophin
casimersen
ind submiss sever ppmo
role dmd exon skip therapi gene therapi world
expect exon skip product continu serv role treatment paradigm
even gene therapi come market expect patient parent strongli
prefer gene therapi chronic manag nearli circumst present
least three distinct patient popul could benefit like util
young dmd patient exact age treat dmd patient gene therapi
establish gener belief younger dmd patient
treat better expect outcom howev patient treat
young age may see efficaci wane quickli cardiomyocyt turnov
substanti higher first year life addit amount skelet
muscl rapidli increas childhood expert believ potent exon
skip therapi ppmo could use bridg patient
dose gene therapi older voit
older dmd popul may candid gene therapi
expect exon skip therapi treatment choic patient
inelig gene therapi whether due age insur restrict
exhaust redos options/high antibodi titer
patient previous treat gene therapi earli experi sma
gene therapi suggest portion patient treat gene therapi clinic
trial eventu requir addit support spinraza children grow
build muscl mass efficaci gene therapi dmd could wane
addit skelet muscl cell turn everi year healthi patient
even absenc skelet muscl growth patient may less
robust transduct extrem limit data exist variabl respons dmd
gene therapi benefit top-up clinician hypothes exon
skip therapi administ proactiv could prolong
benefit gene therapi prevent muscl damag cell turnov
ultim current limit visibl part market could
evolv expect clinic data need gener establish
efficaci exon skip intervent top gene therapi facilit lt
model assign base valuat pmo/ppmo franchis specif
exon valuat assum near-term growth srpt exon skip
franchis driven
continu us growth exondi in-lin consensu continu
growth reflect growth annual number patient treatment
drug launch septemb strong durabl treatment
comment complianc model exondi come market
europ follow complet promovi trial
acceler approv golodirsen exon us plan
file approv later year set potenti approv
expect sale may challeng nippon shinyaku product estim market
entranc demonstr dystrophin express vs golodirsen
acceler approv casimersen exon us
plan file approv us use biopsi data on-going
essenc trial biopsi data expect later
long term base model assum dmd gene therapi come market
therebi reduc popul need exon skip therapi given lack data
ppmos/competitor product assum srpt product captur
exon skip market reflect srpt highli advantag market posit
dmd off-set robust publish dystrophin product competitor
note also develop therapi exon
reflect estim
subsequ exon account dmd popul vs
exon account popul
lgmd posit long-term valu driver
see strong mechanist rational srpt gene therapi approach
favor differenti dmd entir target gene includ
srpt capsid howev unlik dmd natur histori diseas
vari subtyp poorli character literatur leav open
question like market penetr rate appropri lt clinic measur
target five separ lgmd indic togeth repres
market opportun address dmd gene therapi expect
attent investor increas initi clinic data
expect earli steadi newsflow expect
lgmd make current target price reflect basic
assumpt srpt lgmd program address rel smaller popul
lower po current assumpt dmd gene therapi
target five subtyp account lgmd patient
competit clinic develop estim srpt program could
collect gener recur annual revenu repres
total valu annual dmd gene therapi opportun
limb girdl muscular dystrophi lgmd progress muscle-wast genet diseas
symptom usual includ progress muscl weak hip shoulder
individu lgmd eventu lose abil walk everyday activ
get dress becom nearli imposs approv treatment
lgmd care support natur
differ subtyp lgmd caus mutat
differ gene subtyp lgmd differ phenotyp subtyp
associ respiratori cardiac issu result earli mortal even within
particular mutat wide variabl term time diseas onset diseas
preval form lgmd rang pegoraro et
al sarepta explor uniqu gene therapi treatment
collect lgmd subtyp account
figur background lgmd subtyp
predictor diseas sever
first decad life
loss compon
loss ambul usual decad life
often mark progress acut ill
patient may weaken heart muscl cardiac impair
patient sveen ml et al semplicini et al
patient live rel long
live
estim rang
per million
common amish
correl sgcb gene
mutat sarcoglycan protein
first decad life
loss compon
loss ambul decad life fayssoil et al
one studi patient respiratori event year period
home mechan ventil decad life
death decad life
death
decad life
first decad life
loss compon
loss ambul decad life
greater heart involv fayssoil et al
one studi patient respiratori event year period
home mechan ventil decad life
death decad life
death
decad life
estim rang
per million
mutat puerto rican less
sever subtyp al-zaidi
caus dysf gene
may absent
muscl repair
slower progress sarcoglycanopathi
leg gener first affect
loss ambul
associ cardiomyopathi respiratori issu
one
along
million common
jewish popul
possibl degre remain
establish
anoctamin other
protein
initi symptom includ weak wast lower limb
patient remain ambul late adulthood
respiratori heart problem rare
femal often less sever afflict male
one
per million
possibl degre remain
compani data credit suiss estim wohproject org univers exet orphanet fayssoil et al jain foundat musculardystrophyuk org genereview
sarepta lead program could data earli
sarepta lead lgmd program treatment
util capsid deliv full-length -sarcoglycan gene exact design
phase trial known time unclear age patient
treat phase trial begin expect biopsi result
cohort earli
better defin rate diseas progress skelet muscl
male femal ethnic group
abil complet time test within predict
subject bind antibodi titer
comorbid confound interpret result
activ placebo cohort vg/kg
activ placebo cohort vg/kg fiber express
placebo crossov yr read subject
evalu safeti
evalu gene express muscl fiber express
time workspac volum nsaa time-up go
cardiac eject fraction mri ascend stair
n/a cohort day biopsi data earli
expect initi biopsi data like demonstr therapi
get appropri target tissu confid therapeut approach
base profound express level achiev dmd micro-dystrophin studi
sarepta opt use capsid promot
micro-dystrophin studi believ reason dmd
similar patholog phenotyp need target heart skelet muscl
optim program reinforc compel preclin data mous
model treatment associ reduct muscl fibrosi close wt level
statist signific reduct creatin kinas sub u/l level revers
scoliosi restor diaphragm function
figur preclin evid effect
-sarcoglycan month
expert believ evid follow would win biopsi
creatin kinas reduct patient creatin kinas level
rang ck reduct rang similar dmd
micro-dystrophin studi would highli compel
increas -sarcoglycan express autosom recess
therefor expert expect patient would experi impact
protein express comprehens natur studi lgmd
minimum level -sarcoglycan need unknown expert estim
simpli educ guess
improv dystrophin/glycan complex dystrophin/glycan
complex break -sarcoglycan missing/not function restor
complex lead clinic benefit seen dmd trial
temper overenthusiasm program earli stage expert highlight
interpret biopsi data could confound base patient vari
baselin -sarcoglycan level inher subject variabl biopsi
data mtm express level biopsi muscl xlmtm dog model
vari fold dmd micro-dystrophin trial saw varianc biopsi data across
methodolog addit expert mention patient may
nonfunct -sarcoglycan protein make challeng determin
percentag muscl fiber express gene therapi protein lastli initi
steroid regimen may lead temporari reduct ck level short term
could potenti challeng interpret earli clinic find
interpret function data may challeng owe limit natur
think chanc profound function benefit seen follow-up
micro-dystrophin studi saw signific function benefit within day given
underli patholog two diseas goal restor dystro-sarcoglycan
complex think rapid benefit possibl clinic trial howev clear
realist base expect ahead initi data readout
expert believ one possibl hurdl may prove function benefit provid initi
observ benefit overwhelm comprehens natur histori
studi lgmd awar make
determin patient popul enrol clinic trial challeng confound
interpret function data
expert stress even within wide variabl diseas
phenotyp progress underli caus variabl progress
well character literatur mous model suggest primari driver
amount residu protein hasnt confirm natur histori studi
believ unlik us lgmd patient least initi
candid gene therapi initi indic compani suggest phase
gene therapi studi patient ambul thu like
age estim patient within age rang
possibl nonambulatori patient could see benefit improv cardiac
respiratori function believ unclear whether insur provid reimburs
treatment without clinic evid efficaci consid limit publish natur
see littl way competit threat lgmd littl drug discoveri work
done lgmd histor awar gene therapi develop
lgmd therapi clinic atyr pharma resolari shorten
variant protein resokin
explicitli model opportun estim peak sale
could approach recur global sale could approach annual
reflect incid us eu select row countri
enter iv
align preclin
trial submit
preclin safeti dose-
see multipl advantag srpt broad focu lgmd given similar
phenotyp gener capsid use program addit
program use promot program demonstr
preclin efficaci shown earli sign activ isol limb studi
predict
tibiali anterior higher right vs left normal
biopsi due fall fractur
quadricep increas baselin normal
quadricep increas baselin normal
quadricep increas baselin normal
increas baselin
tibiali anterior normal
quadricep normal
activ placebo cohort vg/kg
activ placebo cohort vg/kg fiber express
placebo crossov yr read last subject dose
evalu safeti
evalu gene express muscl fiber express
time workspac volum nsaa time-up go
cardiac eject fraction mri ascend stair
figur preclin bridg data move iv
figur preclin bridg data move iv
posit biopsi data could offer derisk four
lgmd program develop could support increment global
sale opportun program trail posit
fast-follow strengthen sarepta posit leader lgmd space
explicitli model lgmd program pend initi data initi phase
studi sign clinic benefit first one two program could increas
valuat correspond mark increas po program
improv sentiment four lgmd program togeth see five
price compar dmd gene therapi program
npv lgmd repres approxim dcf-driven target
price stand valuat determin use dmd valu compar
lgmd program develop address dmd
owe uncertain natur histori assum lgmd program achiev
rel penetr respect target market compar dmd
variant lgmd studi notabl less sever dmd
assign po rel basi po use
srpt dmd gene therapi reflect lack clinic data complex
need achiev success five distinct program technic risk
dual vector approach off-set initi derisk aav
capsid promot gener use on-going
assum hold monopoli posit target lgmd market
forese futur
arriv target price use blend valuat approach
includ product-bas dcf dcf
dcf model assum discount rate standard discount rate commerci
compani fulli dilut share million tax rate assign five year
termin valu micro-dystrophin gene therapi valu
detail dcf compon includ follow
second valuat scenario support target reflect
increas revenu off-set decreas decreas
pipeline/platform incl mfg gene tx etc
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
adjust base program specif histor probabl success specif
diseas categori standard mind assign follow probabl
success srpt pipelin
micro-dystrophin gene somewhat higher typic
probabl success asset phase develop reflect
strong clinic proof-of-concept intuit mechanist approach
equival
compani cash cash equival june project
net cash use oper
blue sky scenario reflect probabl success dmd gene
therapi probabl success lgmd gene therapi
probabl success casimersen golodirsen grey sky scenario
reflect valu dmd gene therapi valu lgmd gene therapi
poorli design studi inadequ endpoint enough power neg
safety/efficaci signal neg dsmb/health author rule specif
includ
failur exondi confirmatori trial develop candid clinic
trial demonstr efficaci favor risk/benefit profil
emerg safeti issu exondi srpt develop
develop risk associ earlier-stag asset
liquidity/fund difficulti develop candid
manufacturing/suppli risk includ limit suppli disrupt product
batch adher
contamin technic difficulti produc function complex molecul delay
construction/certif new facil inadequ lack materi
qualiti standard manufactur shutdown due
inabl manufactur suffici quantiti exondi pipelin
candid meet clinic commerci demand
difficulti scale gene therapi product meet commerci suppli
commerci risk includ limit lower-than-expect adopt drug
target popul competit clinical/exist agent payor-impos access
restrict price reform and/or restrict and/or control specif
access reimburs challeng exondi futur commerci
price challeng srpt product
research develop expens
sell gener administr expens
profit loss tax
charl martineau pm univers toronto figur balanc sheet
cash equival
prepaid expens current asset
properti equip net
commit conting
amort debt/invest
loss/ dispos asset
chang asset liabil
prepaid expens asset
net cash use oper activ
purchas properti equip
sale asset
purchas invest
sale/matur invest
net cash use invest activ
proce issuanc debt
proce exercis stock option
payment offer cost
payment debt issuanc cost
proce issuanc prefer stock net issuanc cost
proce issuanc common stock net
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
compani mention price
